The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
25 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,044,647 in first-year total cost, median $202,275.
Most frequent study sections
- Special Emphasis Panel[ZRG1 OBT-A (55)]9
- Special Emphasis Panel[ZRG1 OBT-D (55)]6
- Special Emphasis Panel[ZRG1 OBT-B (55)]4
- Special Emphasis Panel[ZRG1 OBT-G (55)]3
- Special Emphasis Panel[ZRG1 OBT-K (55)]2
Most frequent institutions
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE2
- MAYO CLINIC JACKSONVILLE2
- UNIVERSITY OF TX MD ANDERSON CAN CTR2
- CEDARS-SINAI MEDICAL CENTER1
- DANA-FARBER CANCER INST1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Precision Antibody-Based Therapy to Neutralize Epstein-Barr Virus-Associated PTLDs1R21CA232275-01 | OGEMBO, JAVIER GORDON | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $225,765 | ZRG1 |
| 2018 | Exploring immune surveillance in isocitrate dehydrogenase mutant cholangiocarcinoma1R21CA232258-01 | SAHA, SUPRIYA K | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $218,970 | ZRG1 |
| 2018 | Glucocorticoid Receptor degrading bifunctional molecules as therapeutics in prostate cancer1R21CA232233-01 | LISSANU, YONATHAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $208,800 | ZRG1 |
| 2018 | Role of OxLDL in metabolic syndrome-associated resistance of myeloma to proteasome inhibitors1R21CA227414-01 | MEDINA, EDWARD A. | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $199,013 | ZRG1 |
| 2018 | Differential Regulation of Tumor Invasion by RSK Family Isoforms1R21CA215891-01A1 | MENDOZA, MICHELLE CHRISTINE | UNIVERSITY OF UTAH, UT | $198,686 | ZRG1 |
| 2018 | Assessment of gene expression profiles related to hepatocellular carcinoma in HCV: singlecell hepatocyte sequencing as a tool to identify cancer-related genes1R21CA215883-01A1 | DEBES, JOSE DANIEL | UNIVERSITY OF MINNESOTA, MN | $167,385 | ZRG1 |
| 2017 | A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies1R21CA205106-01A1 | OGEMBO, JAVIER GORDON | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $234,992 | ZRG1 |
| 2017 | Primers: Combining Radiotherapy and Immunotherapy using next genertaion radiotherapy biomaterials1R21CA205094-01A1 | NGWA, WILFRED | DANA-FARBER CANCER INST, MA | $229,187 | ZRG1 |
| 2017 | Identification of novel prognostic markers in triple-negative breast cancers in African American Women1R21CA220518-01 | SANCHEZ, IRMA | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $221,198 | ZRG1 |
| 2017 | Epigenetic Regulation by CHD7 in Colon Cancer1R21CA215108-01 | ESTECIO, MARCOS | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $208,800 | ZRG1 |
| 2017 | Targeting hyaluronan synthesis and signaling with BET inhibitors in pancreatic cancer1R21CA220625-01 | KUMAR, KRISHAN | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $206,190 | ZRG1 |
| 2017 | Prostate Cancer and Obesogenic Factors1R21CA216052-01 | MACIAS, EVERARDO | CEDARS-SINAI MEDICAL CENTER, CA | $203,914 | ZRG1 |
| 2017 | MyD88-dependent mechanisms of Helicobacter pylori-induced gastric cancer progression1R21CA210227-01A1 | OBONYO, MARYGORRET | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $202,275 | ZRG1 |
| 2017 | PDL1 expression on B cells: a potential marker of pre-tumor cells in AIDS-NHL1R21CA220475-01 | EPELDEGUI, MARTA | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $202,275 | ZRG1 |
| 2017 | Targeting melanoma hypoxia with lactic acid bacterium L. lactis1R21CA210202-01A1 | GOMEZ-GUTIERREZ, JORGE G | UNIVERSITY OF LOUISVILLE, KY | $200,970 | ZRG1 |
| 2017 | Treating prostate cancer by pharmacological coinhibition of the Warburg effect and lipogenesis1R21CA205096-01A1 | FLAVENY, COLIN ASHTON | SAINT LOUIS UNIVERSITY, MO | $197,708 | ZRG1 |
| 2017 | Exploring the Mechanisms of Sarcoma-Associated Cachexia1R21CA199472-01A1 | WEISS, KURT RICHARD | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $192,967 | ZRG1 |
| 2017 | Targeting Cyclin E in Ovarian Cancer with Histone Deacetylase Inhibitors1R21CA210210-01A1 | KHABELE, DINEO | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $182,020 | ZRG1 |
| 2017 | Role of the mRNA 3’ processing factor CstF-50 in regulating the BRCA1/BARD1 E3 ubiquitin ligase activity during the DNA damage response1R21CA204610-01A1 | KLEIMAN, FRIDA E | HUNTER COLLEGE, NY | $169,650 | ZRG1 |
| 2016 | Ect2 Function in Lung Adenocarcinoma Initiation and Maintenance1R21CA204938-01 | JUSTILIEN, VERLINE | MAYO CLINIC JACKSONVILLE, FL | $219,491 | ZRG1 |
| 2016 | Exposomic approach to understand the effect of immigration and genetic ancestry on breast cancer risk in U.S. Latinas1R21CA210023-01 | FEJERMAN, LAURA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $216,768 | ZRG1 |
| 2016 | Understanding Breast Cancer Metastasis to Lymph Node1R21CA199621-01A1 | MOHAMMED, SULMA IBRAHIM | PURDUE UNIVERSITY, IN | $202,275 | ZRG1 |
| 2016 | Role of Human Cerebrospinal Fluid Chemokines in the Invasiveness of Human Glioblastoma1R21CA199295-01A1 | GUERRERO-CAZARES, HUGO | MAYO CLINIC JACKSONVILLE, FL | $199,342 | ZRG1 |
| 2016 | Dissecting gastric cancer clonality with genomic analyses and patient xenografts1R21CA199631-01A1 | CARVAJAL CARMONA, LUIS GUILLERMO | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $170,738 | ZRG1 |
| 2016 | RhoG Signaling in Invadopodia1R21CA194776-01A1 | GARCIA-MATA, RAFAEL | UNIVERSITY OF TOLEDO, OH | $165,268 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.